Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $106

Mizuho analyst Salim Syed has maintained an 'Outperform' rating on BridgeBio Pharma (NASDAQ: BBIO) and raised the price target from $91 to $106. This adjustment reflects a positive outlook on the company's performance.